Answers are grounded in this paper and cite their sources.
Review summarizes advances in nucleic acid materials for protein degradation enhancement in precision medicine, highlighting challenges.
Targeted protein degradation systems (TPDS), mainly including proteolysis-targeting chimeras (PROTACs) and lysosome-targeting chimeras (LYTACs), have been widely employed in the development of precision medicines. As a class of biological macromolecules, nucleic acids, with excellent programmability and remarkable biocompatibility, have been successfully integrated into the TPDS to improve their specificity and efficacy. In this review, the recent progress about nucleic acid materials in the targeted protein degradation systems for various biomedical applications are summarized. Nucleic acid materials developed for cell targeting, as warheads, and as scaffolds in TPDS are highlighted. Furthermore, the challenges and future prospects of nucleic acid materials-based TPDS for in vivo biomedical applications are discussed.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: